Printer Friendly

IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL

 IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS
 ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
 MIAMI, Aug. 3 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that its wholly owned subsidiary Baker Cummins Pharmaceuticals, Inc., received the approval from the United States Food and Drug Administration of its Abbreviated New Drug Application for the off- patent pharmaceutical product, 240 mg. Verapamil HCL ER tablets. Verapamil HCL ER is a sustained release product administered once per day for the treatment of hypertension. The product is a generic equivalent of the products marketed by G.D. Searle & Co. under the brand name Calan(R) SR and by Knoll Pharmaceuticals under the brand name Isoptin(R) SR. Baker Cummins Pharmaceuticals will begin selling the product after it has successfully completed a pre-marketing inspection of its production process by the United States Food and Drug Administration. Calan(R) is a registered trademark of G.D. Searle & Co. Isoptin(R) is a registered trademark of Knoll A.G.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over the counter pharmaceuticals in the United States; Best Generics, Inc., a national distributor of off-patent pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 8/3/92 R
 /CONTACT: Richard C. Pfenniger Jr., senior vice president Legal Affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation ST: Florida IN: MTC SU:


JB-SS -- FL002R -- 6089 08/03/92 11:21 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1992
Words:326
Previous Article:APPLEBEE'S REPORTS SECOND QUARTER EARNINGS MORE THAN DOUBLE YEAR EARLIER
Next Article:CLINTEC ACQUIRES FRENCH COMPANY
Topics:


Related Articles
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
NEW JERSEY STATE FORMULARY APPROVES BAKER NORTON'S GENERIC VERAPAMIL
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR 180 MG. VERAPAMIL TABLETS
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters